Ticker: NASDAQ: GANX
Founded: 2017
Headquarters: Bethesda, Maryland, USA
CEO: Robert L. J. W. Hopf
Status: Public company
Market Cap: ~$30 million (2026)
Website: gaintherapeutics.com
Gain Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutic chaperones for neurodegenerative diseases and lysosomal storage disorders. Founded in 2017 and headquartered in Bethesda, Maryland, Gain utilizes a proprietary computational platform called SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules) to identify small molecules that can stabilize and restore function to misfolded proteins[1].
The company's approach represents a paradigm shift in treating protein misfolding diseases — rather than attempting to clear accumulated toxic proteins or replace missing enzymes entirely, Gain's therapeutic chaperones help restore the natural function of endogenous proteins. This approach has the potential to modify disease progression rather than merely addressing symptoms.
Gain Therapeutics went public in 2021, listing on the NASDAQ stock exchange under the ticker GANX. The company has raised over $40 million through its IPO and subsequent financing rounds to advance its clinical pipeline.
Gain Therapeutics was founded based on research conducted at the University of Maryland and Johns Hopkins University, with a focus on applying computational biology to protein stabilization. The company's SEE-Tx platform emerged from over a decade of academic research on protein misfolding and therapeutic chaperone design.
The company's name reflects its core scientific approach — "Gain" refers to gaining function, as opposed to the loss of function that characterizes many neurodegenerative diseases. This naming reflects the company's mission to develop therapies that restore protein function rather than simply reducing toxic protein accumulation.
| Year | Event |
|---|---|
| 2017 | Company founded in Bethesda, MD |
| 2018 | Series A financing: $5.5 million |
| 2020 | Series B financing: $12 million; SEE-Tx platform validated |
| 2021 | IPO on NASDAQ: $25 million gross proceeds |
| 2023 | GT-02287 enters Phase 1 clinical trials |
| 2024 | Phase 1b trial initiated in GBA1-PD |
| 2025 | Phase 1b interim data expected |
The proprietary SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules) platform represents Gain's core technological advantage. This computational approach enables the identification of small molecule chaperones that can stabilize misfolded proteins[2].
Key capabilities include:
Unlike traditional drug discovery approaches that focus on inhibiting or activating protein function, SEE-Tx is specifically designed to restore protein function. This makes it particularly applicable to:
The SEE-Tx platform has been validated across multiple protein targets:
GT-02287 is Gain's lead clinical candidate — a small molecule glucocerebrosidase (GCase) modulator for the treatment of Parkinson's disease[3].
Mechanism of Action:
GT-02287 is an allosteric small molecule chaperone that binds to GCase, stabilizing its proper conformation and increasing enzyme activity. This approach addresses the underlying enzymatic deficiency that contributes to Parkinson's disease pathology.
Pharmacological Properties:
Clinical Development:
Target Indications:
GT-0234 demonstrates the versatility of the SEE-Tx platform across therapeutic areas. This candidate targets Pompe disease, a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA).
Current Status: Preclinical development
| Program | Indication | Target | Development Stage |
|---|---|---|---|
| GT-02287 | Neuronopathic Gaucher Disease | GCase | Preclinical |
| GT-02287 | Dementia with Lewy Bodies | GCase | Preclinical |
| GT-02287 | Alzheimer's Disease | GCase | Preclinical |
| GT-02287 | Parkinson's Disease (idiopathic) | GCase | Phase 1b |
| GT-0234 | Pompe Disease | GAA | Preclinical |
| Undisclosed | GM1 Gangliosidosis | GLB1 | Preclinical |
| Undisclosed | Krabbe Disease | GALC | Discovery |
| Undisclosed | Fabry Disease | GLA | Research |
Gain maintains an active research portfolio exploring additional targets:
Glucocerebrosidase (GCase) is a lysosomal enzyme encoded by the GBA1 gene that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose[4]. This enzyme plays a critical role in lipid metabolism within lysosomes.
GCase dysfunction contributes to neurodegeneration through multiple mechanisms:
Mutations in the GBA1 gene represent the most common genetic risk factor for Parkinson's disease:
This strong genetic link suggests that restoring GCase function could benefit not only GBA1 mutation carriers but also the broader Parkinson's disease population.
Gain's therapeutic chaperone approach offers several advantages over alternative strategies:
Compared to enzyme replacement therapy:
Compared to gene therapy:
Compared to antibody therapies:
Gain's strategic priorities center on three main areas:
Gain seeks strategic partnerships to accelerate development:
Gain competes with other companies developing Parkinson's disease therapies:
Gain believes its allosteric small molecule approach offers advantages in terms of brain penetration, dosing convenience, and mechanism of action.
| Event | Year | Amount | Notes |
|---|---|---|---|
| Seed | 2017 | $2 million | Founder funding |
| Series A | 2018 | $5.5 million | Product development |
| Series B | 2020 | $12 million | Platform expansion |
| IPO | 2021 | $25 million | Public offering |
| PIPE | 2022 | $8 million | Post-IPO financing |
Gain's R&D expenses have increased as programs advance into clinical development:
The board includes representatives from pharmaceutical development, finance, and biotech industry leadership.
Leading academic and industry scientists provide guidance on drug development strategy and scientific direction.
Gain is committed to ensuring patients can access its therapies:
Gain maintains commitment to responsible corporate practices:
Looking ahead, Gain Therapeutics is positioned to achieve several key milestones:
Gain Therapeutics. Corporate Website. 2026. ↩︎
Gain Therapeutics. SEE-Tx Platform Technology. 2026. ↩︎
Gain Therapeutics. Clinical Pipeline. 2026. ↩︎
GBA1 and Parkinson's Disease. PD Genetics Initiative. 2026. ↩︎